Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thiakis Ltd.

This article was originally published in Start Up

Executive Summary

Thiakis Ltd., a spin-out of Imperial College in London, aims to commercialize an effective anti-obesity treatment based on a peptide hormone called oxyntomodulin, which is released primarily by the intestines after food is consumed, and seems to rein in appetite.

You may also be interested in...



Start-Ups in Obesity

The unanimous rejection of Sanofi-Aventis' obesity drug rimonabant by an FDA Advisory Committee in June hasn't put off the host of firms, large and small, seeking an answer to the obesity epidemic. Despite the many drug casualties in this area, still, it seems, no approach is ruled out.

The IP Land Grab: New UK Tech Transfer Models

As VCs continue to woo later-stage assets, a new breed of companies has stepped in upstream to help UK universities commercialize their IP. The models vary, and it's unclear how successful they'll be either for investors, or for universities. But the attention and money they're attracting to the area are welcome.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel